CREATE Therapeutics

CREATE Therapeutics is a biotechnology company pioneering the use of synthetic biology and epigenetic programming to develop transformative regenerative medicines. Utilizing its proprietary CREATE (Cellular Reprogramming and Epigenetic Antigen Targeting Engineering) platform, the company designs synthetic gene circuits capable of precisely orchestrating cellular identity and function. This technology allows for the in vivo reprogramming of diseased tissues, aiming to reverse chronic conditions such as liver fibrosis by restoring healthy cellular states. CREATE Therapeutics represents a frontier in "living medicines," moving beyond simple gene replacement to complex, logic-gated control of gene expression. The company's approach focuses on direct in situ tissue repair, potentially offering a more scalable alternative to traditional cell replacement therapies.